Cambridge, MA-based gene editing company Editas Medicine (NASDAQ: EDIT) has named Charles Albright its chief scientific officer. Albright was most recently the VP of genetically defined diseases and genomics at Bristol-Myers Squibb, and held positions at Incyte and DuPont Pharmaceuticals before that.
From Our Editors · Special Report
The AI, Big Data, and R&D Boom
Sponsored · Webinar
How Functional Cell-based Assays Support Clinical Programs Managing Proinflammatory Cytokines Associated with High Mortality
Eurofins DiscoverX
From Our Editors · Special Report
Becoming the Cell & Gene Therapy Hub
